Aptevo Therapeutics (NASDAQ:APVO) Stock Passes Below 50-Day Moving Average – What’s Next?

Aptevo Therapeutics Inc. (NASDAQ:APVO) shares crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $4.69 and traded as low as $4.41. Aptevo Therapeutics shares last traded at $4.55, with a volume of 17,385 shares trading hands.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings raised shares of Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. Wall Street Zen raised shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 29th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Aptevo Therapeutics presently has an average rating of “Hold”.

Aptevo Therapeutics Price Performance

The company has a market capitalization of $5.69 million, a price-to-earnings ratio of -0.02 and a beta of 1.64. The business’s 50 day simple moving average is $4.69 and its 200 day simple moving average is $10.96.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($6.41) EPS for the quarter, meeting analysts’ consensus estimates of ($6.41). As a group, analysts expect that Aptevo Therapeutics Inc. will post -24.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 8.06% of the stock is owned by institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.